Suppl. Figure 1: Global weightings of the criteria (Eigenvalue)

Suppl. Figure 2: Global weightings of the criteria (eigenvalues) stratified by perceived potential QoL improvement

**Suppl. Table 1: Results of the AHP (weightings of the criteria and sub-criteria): subgroup divided by gender**

|  |  |  |
| --- | --- | --- |
|   | **Men (N=41)** | **Women (N=20)** |
|  **Criterion** **Sub-criterion** | **wlocal 1st tier** | **wlocal 2nd tier** | **wglobrel** | **Rank** | **wlocal 1st tier** | **wlocal 2nd tier** | **wglob rel** | **Rank** |
| **Frequency of apheresis** | 0.138 |   |   | 4 | 0.087 |   |   | 4 |
|  No apheresis per month |   | 0.466 | 0.064 |  |   | 0.410 | 0.036 |  |
|  2 aphereses per month |   | 0.382 | 0.053 |  |   | 0.405 | 0.035 |  |
|  4 aphereses per month |   | 0.151 | 0.021 |  |   | 0.185 | 0.016 |  |
| **Risk of drop in blood pressure** | 0.067 |   |   | 6 | 0.061 |   |   | 6 |
|  No risk of drop in blood pressure (0%) |   | 0.460 | 0.031 |  |   | 0.572 | 0.035 |  |
|  Low risk of drop in blood pressure (2.5%) |   | 0.384 | 0.026 |  |   | 0.296 | 0.018 |  |
|  High risk of drop in blood pressure (5 %) |   | 0.157 | 0.011 |  |   | 0.132 | 0.008 |  |
| **Reduction of LDL-C level in blood** | 0.351 |   |   | 1 | 0.385 |   |   | 1 |
|  High reduction of LDL-C level in blood (by 60%) |   | 0.695 | 0.244 |  |   | 0.760 | 0.293 |  |
|  Medium reduction of LDL-C level in blood (by 35%) |   | 0.230 | 0.081 |  |   | 0.178 | 0.069 |  |
|  Low reduction of LDL-C level in blood (by 10%) |   | 0.075 | 0.026 |  |   | 0.062 | 0.024 |  |
| **Number of additional injections** | 0.072 |   |   | 5 | 0.083 |   |   | 5 |
|  No additional injections per month |   | 0.299 | 0.022 |  |   | 0.396 | 0.033 |  |
|  1 additional injection per month |   | 0.449 | 0.032 |  |   | 0.336 | 0.028 |  |
|  2 additional injections per month |   | 0.252 | 0.018 |  |   | 0.268 | 0.022 |  |
| **Skin problems at injection site** | 0.054 |   |   | 7 | 0.046 |   |   | 7 |
|  No skin problems at injection site |   | 0.571 | 0.031 |  |   | 0.689 | 0.032 |  |
|  Mild skin problems at injection site  |   | 0.273 | 0.015 |  |   | 0.228 | 0.011 |  |
|  Moderate skin problems at injection site  |   | 0.157 | 0.008 |  |   | 0.083 | 0.004 |  |
| **Risk of myopathy** | 0.163 |   |   | 2 | 0.165 |   |   | 3 |
|  No risk of myopathy (0%) |   | 0.608 | 0.099 |  |   | 0.722 | 0.119 |  |
|  Medium risk of myopathy (5%)  |   | 0.299 | 0.049 |  |   | 0.213 | 0.035 |  |
|  High risk of myopathy (10 %) |   | 0.093 | 0.015 |  |   | 0.065 | 0.011 |  |
| **Risk of neurocognitive impairment** | 0.155 |   |   | 3 | 0.172 |   |   | 2 |
|  No risk of neurocognitive impairment (0%) |   | 0.671 | 0.104 |  |   | 0.756 | 0.130 |  |
|  Medium risk of neurocognitive impairment (1%)  |   | 0.239 | 0.037 |  |   | 0.193 | 0.033 |  |
|  High risk of neurocognitive impairment (3%)  |   | 0.089 | 0.014 |  |   | 0.051 | 0.009 |  |
| *Consistency ratio* |  |  | CR: 0.049 |  |  | CR: 0.086 |